Abstract:Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase 2-3 ORIENT-32 study aimed to assess sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma. Methods This randomised, open-label, phase 2-3 study was done at 50 clinical sites in China. Patients aged 18 years or older with histologically or cytologically diagnosed or clinically confirmed unresectable or metastatic hepatocellular carcinoma, no previous systemic treatment, and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were eligible for inclusion. In the phase 2 part of the study, patients received intravenous sintilimab (200 mg every 3 weeks) plus intravenous IBI305 (15 mg/kg every 3 weeks). In the phase 3 part, patients were randomly assigned (2:1) to receive either sintilimab plus IBI305 (sintilimab-bevacizumab biosimilar group) or sorafenib (400 mg orally twice daily; sorafenib group), until disease progression or unacceptable toxicity. Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified by macrovascular invasion or extrahepatic metastasis, baseline alpha-fetoprotein, and ECOG performance status. The primary endpoint of the phase 2 part of the study was safety, assessed in all patients who received at least one dose of study drug. The co-primary endpoints of the phase 3 part of the study were overall survival and independent radiological review committee (IRRC)-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT03794440. The study is closed to new participants and follow-up is ongoing for long-term outcomes. Findings Between Feb 11, 2019 and Jan 15, 2020, we enrolled 595 patients: 24 were enrolled directly into the phase 2 safety run-in and 571 were randomly assigned to sintilimab-bevacizumab biosimilar (n=380) or sorafenib (n=191). In the phase 2 part of the trial, 24 patients received at least one dose of the study drug, with an objective response rate of 25 & middot;0% (95% CI 9 & middot;8-46 & middot;7). Based on the preliminary safety and activity data of the phase 2 part, in which grade 3 or worse treatment-related adverse events occurred in seven (29%) of 24 patients, the randomised phase 3 part was started. At data cutoff (Aug 15, 2020), the median follow-up was 10 & middot;0 months (IQR 8 & middot;5-11 & middot;7) in the sintilimab-bevacizumab biosimilar group and 10 & middot;0 months (8 & middot;4-11 & middot;7) in the sorafenib group. Patients in the sintilimab-bevacizumab biosimilar group had a significantly longer IRRC-assessed median progression-free survival (4 & middot;6 months [95% CI 4 & middot;1-5 & middot;7]) than did patients in the sorafenib group (2 & middot;8 months [2 & middot;7-3 & middot;2]; stratified hazard ratio [HR] 0 & middot;56, 95% CI 0 & middot;46-0 & middot;70; p<0 & middot;0001). In the first interim analysis of overall survival, sintilimab-bevacizumab biosimilar showed a significantly longer overall survival than did sorafenib (median not reached [95% CI not reached-not reached] vs 10 & middot;4 months [8 & middot;5-not reached]; HR 0 & middot;57, 95% CI 0 & middot;43-0 & middot;75; p<0 & middot;0001). The most common grade 3-4 treatment-emergent adverse events were hypertension (55 [14%] of 380 patients in the sintilimab-bevacizumab biosimilar group vs 11 [6%] of 185 patients in the sorafenib group) and palmar-plantar erythrodysaesthesia syndrome (none vs 22 [12%]). 123 (32%) patients in the sintilimab- bevacizumab biosimilar group and 36 (19%) patients in the sorafenib group had serious adverse events. Treatment related adverse events that led to death occurred in six (2%) patients in the sintilimab-bevacizumab biosimilar group (one patient with abnormal liver function, one patient with both hepatic failure and gastrointestinal haemorrhage, one patient with interstitial lung disease, one patient with both hepatic faliure and hyperkalemia, one patient with upper gastrointestinal haemorrhage, and one patient with intestinal volvulus) and two (1%) patients in the sorafenib group (one patient with gastrointestinal haemorrhage and one patient with death of unknown cause). Interpretation Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients.

Pembrolizumab Versus Placebo As Second-Line Therapy in Patients from Asia with Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial

Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study.

Pembrolizumab Plus Chemotherapy for Chinese Patients with Metastatic Squamous NSCLC in KEYNOTE-407

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial

Pembrolizumab Plus Chemotherapy for Advanced Non-Small-cell Lung Cancer Without Tumor PD-L1 Expression in Asia

Abstract CT284: Phase 3 KEYNOTE-937: Adjuvant Pembrolizumab Versus Placebo in Patients with Hepatocellular Carcinoma and Complete Radiologic Response after Surgical Resection or Local Ablation

Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Abstract CT222: Pembrolizumab (pembro) for Previously Treated Advanced Hepatocellular Carcinoma (ahcc): Meta-analysis of the Phase 3 KEYNOTE-240 and KEYNOTE-394 Studies

Atezolizumab with or Without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): an Open-Label, Multicentre, Phase 1b Study

Health-related Quality of Life (hrqol) Impact of Pembrolizumab (pembro) Plus Best Supportive Care (BSC) Versus Placebo (PBO) Plus BSC As Second-Line (2L) Therapy in Patients (pts) in Asia with Advanced Hepatocellular Carcinoma (HCC): Phase 3 KEYNOTE-394 Study.

Phase 2 Study of the PD-1 Inhibitor Serplulimab Plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma

A Randomized Multicentered Phase II Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Failed or Intolerable to Prior Systemic Treatment.

Toripalimab Combined with Anlotinib As the Second-Line Treatment for Advanced Hepatocellular Carcinoma Patients: a Prospective, Single Arm Phase II Clinical Study

Camrelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma: a Multicentre, Open-Label, Parallel-Group, Randomised, Phase 2 Trial

A Phase Ib Study of Pembrolizumab As Second-Line Therapy for Chinese Patients with Advanced or Metastatic Melanoma (KEYNOTE-151)

1016Tip LEAP-012 Trial in Progress: Pembrolizumab Plus Lenvatinib and Transarterial Chemoembolization (TACE) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC) Not Amenable to Curative Treatment

Perioperative Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma: A Single-Arm, Multi-Center, Phase II Trial (Neoleap-Hcc).